VIFOR-PHARMA-GROUP
Regulatory News:
At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council, regarding measures against containment of the coronavirus (COVID-19), shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 69% of the share capital was represented.
Shareholder approvals
Shareholders approved the 2019 Vifor Pharma Annual Report, the Vifor Pharma Ltd. 2019 Annual Financial Statements, and the Vifor Pharma Group 2019 Consolidated Financial Statements as well as an extension of the Authorized Capital until 14 May 2022 by approving the respective amendment to the Articles of Association. The maximum possible 2020 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2019 Remuneration Report in a consultative vote. Shareholders discharged the members of the Board of Directors and the Corporate Executive Committee for the financial year 2019. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders on 20 May 2020.
Board of Directors re-elections
The Annual General Meeting re-elected all members proposed and elected Gilbert Achermann as new member of the Board of Directors. Shareholders also elected Jacques Theurillat as new Chairman of the Board of Directors, succeeding Etienne Jornod who decided not stand for re-election after 25 years. The Board of Directors sincerely thanks him for many years of distinguished service and recognized his long-standing and successful leadership by appointing him as Honorary Chairman.
The Board of Directors is now composed of the following members: Jacques Theurillat (Chairman), Gilbert Achermann, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony, Kim Stratton and Dr. Gianni Zampieri.
Remuneration Committee confirmed
The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of one year: Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, and Dr. Sue Mahony.
Vifor Pharma Group is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP22.1.2026 15:00:00 CET | Press release
Rimini Agentic UX™ Solutions, Powered by ServiceNow®, deliver enhanced productivity, greater agility and reduced operating cost while being quick, easy and economical to deploy over the top of existing ERP Software releases without any required upgrades or migrations Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of its first 20 innovative Rimini Agentic UX™ Solutions, Powered by ServiceNow®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122013155/en/ Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP Solving Real Business Challenges Now with Agentic AI ERP Rimini Agentic UX Solutions are already in production and helping organizations achieve better busines
LoungePair Brings on Former LoungeBuddy CEO, Enters Agreements with Vietnam Airlines, Auckland Airport22.1.2026 15:00:00 CET | Press release
Travel-tech company LoungePair has brought on LoungeBuddy founder and former American Express executive Tyler Dikman as a key advisor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122515067/en/ Tyler Dikman, joins LoungePair as Key Advisor The company has also signed a key partnership with Vietnam Airlines to power its new Lotusmiles Lounges platform and has added Auckland Airport's Strata Lounge to its network. LoungePair provides on-demand and walk-up airport lounge access without the need for additional memberships, reward programmes, or loyalty status. Travel Tech Expert Tyler Dikman Joins as Advisor Tyler Dikman is the co-founder and former CEO of LoungeBuddy, the airport lounge booking platform acquired by American Express in 2019. Following the acquisition, he served as Vice President of Global Premium Products and Benefits at American Express, leading the integration of LoungeBuddy and helping shape travel exper
Lone Star Acquires Alliance Ground International22.1.2026 14:55:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire Alliance Ground International (“AGI”), a leading North American airport services provider, from Greenbriar Equity Group and Audax Private Equity. Financial terms of the transaction were not disclosed. Founded in 1987 and headquartered in Miami, AGI operates in over 60 airports in North America with a workforce of more than 12,000 professionals. The company provides mission-critical, outsourced services that enable the efficient movement of cargo and passenger aircraft through major airport hubs. AGI’s core business is air cargo handling, supported by passenger terminal, ground handling and other related services. Its integrated service offering, strategic on-airport footprint and long-standing customer relationships position AGI as a trusted partner to cargo carriers and passenger airlines, supporting airport operations and global trade flows. L
Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release
Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom